ANXA1
ANXA1 (annexin A1, also known as ANX1 or LPC1) is a membrane-localised, phospholipid-binding member of the annexin family. It inhibits phospholipase A2, has anti-inflammatory activity and promotes the resolution of inflammation and wound healing. Browse Assay Genie's current range of ANXA1 research reagents below, or read on for the biology behind the target.
ANXA1 functions at least in part by activating the formyl peptide receptors and their downstream signalling cascades. Through these receptors it promotes chemotaxis of granulocytes and monocytes, and it acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2. It also promotes rearrangement of the actin cytoskeleton, cell polarisation and cell migration, and it promotes the resolution of inflammation and wound healing.
The protein encoded by the ANXA1 gene is a membrane-localised phospholipid-binding protein that inhibits phospholipase A2 and has anti-inflammatory activity. UniProt records a broad subcellular distribution: nucleus, cytoplasm, cilium, early endosome and endosome membrane, secretory vesicle lumen and phagocytic cup, as well as the plasma membrane (including apical, basolateral and lateral membranes). It is also found as a secreted protein in the extracellular space and in extracellular exosomes. This range reflects its dual roles inside cells and as an extracellular ligand for receptors.
ANXA1 belongs to the annexin family and is classified by HGNC within both the annexins and receptor ligands gene groups. Mouse and rat each have an orthologous Anxa1 gene. NCBI Gene notes that loss of function or expression of this gene has been detected in multiple tumours, which makes the annexin A1 protein a point of interest for researchers studying inflammation, cell migration and cancer biology.
ANXA1 has anti-inflammatory activity, inhibits phospholipase A2 and promotes the resolution of inflammation.
It promotes chemotaxis of granulocytes and monocytes through formyl peptide receptors and enhances neutrophil release of CXCL2.
ANXA1 promotes actin cytoskeleton rearrangement, cell polarisation and migration, and supports wound healing.
Loss of function or expression of the ANXA1 gene has been detected in multiple tumours, prompting study of its role in cancer.
ANXA1 acts at least in part by activating formyl peptide receptors and their downstream signalling. It promotes granulocyte and monocyte chemotaxis, actin rearrangement, cell polarisation and migration, and the resolution of inflammation and wound healing. It also inhibits phospholipase A2.
The HGNC-approved name is annexin A1, and the symbol is ANXA1. Aliases include ANX1 and LPC1. UniProt lists the protein as Annexin A1. The gene is also grouped with annexins and receptor ligands. Search under any of these names when reviewing the literature.
Mouse and rat both carry an orthologous Anxa1 gene, so the protein can be studied in rodent models; check the datasheet of any product for its validated reactivity. NCBI Gene reports that loss of function or expression of ANXA1 has been detected in multiple tumours.
Other annexin family members that bind phospholipids and take part in membrane and inflammatory biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P04083; product specifications from Assay Genie datasheets.